Last edition
News about "Philogen "
Sun Pharmaceutical’s partner Philogen, a Swiss-Italian biotechnology company, has provided an update on the Phase III FIBROSARC trial evaluating Fibromun (L19TNF) in combination with doxorubicin versus doxorubicin alone as first-line treatment for patients with advanced or metastatic Soft Tissue Sarcoma (STS).
Philogen | 12/11/2025 | By Dineshwori
Philogen Completes Patient Enrollment of Phase III FIBROSARC Trial in STS
All ongoing Fibromun trials remain on track with their expected timelines.
Philogen | 05/02/2025 | By Aishwarya | 908
Sun Pharma Signs Global Exclusive Deal with Philogen for Commercializing FIBROMUN
Under the terms of the agreement, Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun.
Philogen | 01/10/2024 | By Aishwarya | 395
EMA Approves Marketing Authorization Application of Nidlegy
Philogen and Sun Pharmaceutical Industries Ltd. have announced that the European Medicines Agency (EMA) validated the submission of the Marketing Authorization Application (MAA) for Nidlegy.
Philogen | 05/07/2024 | By Aishwarya | 346
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy